Your browser doesn't support javascript.
loading
Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China.
Chen, Yu-Cheng; Dai, Hai-Long; Liu, Chun-Li; Li, Jiang; Ji, Qiu-Shang; Cao, Yun-Shan; Xiao, Jing; Jian, Rong; Zhuo, Jian-Min; Luo, Xin-Chao; Gu, Hong.
Afiliação
  • Chen YC; Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.
  • Dai HL; Department of Cardiology, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Liu CL; Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li J; Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.
  • Ji QS; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan, China.
  • Cao YS; Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China.
  • Xiao J; Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd, Beijing, China.
  • Jian R; Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd, Shanghai, China.
  • Zhuo JM; Department of Statistics & Decision Sciences, Janssen China R&D, Shanghai, China.
  • Luo XC; Department of Statistics & Decision Sciences, Janssen China R&D, Shanghai, China.
  • Gu H; Department of Pediatric Cardiology, Beijing Anzhen Hospital, Beijing, China.
Curr Med Res Opin ; : 1-10, 2024 Aug 01.
Article em En | MEDLINE | ID: mdl-39044676
ABSTRACT

BACKGROUND:

Macitentan, either as monotherapy or part of combination therapy, improved clinical outcomes in patients with pulmonary artery hypertension (PAH) in clinical trials. Evidence on the effectiveness and safety of macitentan administered in real-world clinical practice in China is limited.

METHODS:

This real-world, retrospective, multicenter chart review study was conducted at seven hospitals in China. Adult patients with a diagnosis of PAH who initiated macitentan and had medical assessments at 3-7 months after macitentan initiation were included. The primary outcomes were changes in the World Health Organization functional class (WHO-FC), 6-min walk distance (6MWD), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)/B-type natriuretic peptide from baseline to first follow-up visit (months 3-7). Serious adverse events (SAEs) and adverse drug reactions (ADRs) of macitentan were collected.

RESULTS:

From 30 August 2021 to 31 March 2022, 214 eligible patients were included in the safety analysis set and 105 patients were included in the analysis of effectiveness. At the first follow-up visit compared with baseline, significant changes in WHO-FC were observed (p = .04), 93.5% patients had their WHO-FC improved (25.8%) or maintained (67.7%). 6MWD changed by a mean (standard deviation [SD]) of 45.0 (81.4) meters (p < .001), with 94.7% having their 6MWD improved (34.7%) or maintained (60.0%). The mean (SD) of NT-proBNP decreased from 1667.4 (3233.0) ng/L to 1090.0 (2230.1) ng/L (p < .001). In the safety analysis set, 24 (11.2%) patients experienced at least one ADR and/or SAE. ADRs and SAEs were reported in 11 (5.1%) and 18 (8.4%), respectively. No deaths or unexpected safety events were observed.

CONCLUSION:

This study provided real-world evidence on the clinical benefits and good tolerance of macitentan in Chinese patients with PAH treated in routine clinical practice.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Med Res Opin Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Med Res Opin Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China